Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Wall Street expects flat earnings compared to the year-ago quarter on lower revenues when Avantor, Inc. (AVTR) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 7. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly earnings of $0.25 per share in its upcoming report, which represents no change from the year-ago quarter.
Revenues are expected to be $1.71 billion, down 0.7% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.31% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Avantor?
For Avantor, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.93%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Avantor will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Avantor would post earnings of $0.25 per share when it actually produced earnings of $0.26, delivering a surprise of +4%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Avantor doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Cencora (COR), another stock in the Zacks Medical Services industry, is expected to report earnings per share of $3.50 for the quarter ended December 2024. This estimate points to a year-over-year change of +6.7%. Revenues for the quarter are expected to be $78.12 billion, up 8.1% from the year-ago quarter.
The consensus EPS estimate for Cencora has been revised 1.9% higher over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.63%.
When combined with a Zacks Rank of #2 (Buy), this Earnings ESP indicates that Cencora will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Investment Research
Labcorp Holdings Inc. LH, or Labcorp, is slated to report its fourth-quarter 2024 results on Feb. 6 before the opening bell.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The renowned laboratory service provider reported adjusted earnings of $3.50 in the last reported quarter, topping the Zacks Consensus Estimate by 0.56%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 2.87%.
LH’s Q4 Estimates
The Zacks Consensus Estimate for Labcorp’s fourth-quarter 2024 revenues is pegged at $3.31 billion. This suggests a 9.3% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its fourth-quarter 2024 EPS is expected to improve by 3% to $3.40.
Estimate Revision Trend Ahead of Labcorp’s Q4 Earnings
Estimates for Labcorp’s Q4 earnings have remained constant at $3.40 in the past 60 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
Diagnostics Laboratories (Dx)
The segment is likely to have continued its strong momentum in the fourth quarter of 2024, driven by both organic growth and acquisitions. Labcorp may have furthered its strategic priorities by being the ‘partner of choice’ with health systems and regional local laboratories, allowing enhanced services for patients and providers. In the third quarter of 2024, the company acquired select assets and molecular testing location of Lab Works to expand access to comprehensive testing and laboratory services in Birmingham, AL. Additionally, Labcorp closed the acquisition of select operating assets of Ballad Health outreach lab services.
In September 2024, Labcorp acquired BioReference Health's laboratory testing businesses outside of New York and New Jersey, focusing on clinical diagnostics and reproductive and women's health. Further, its collaboration with Naples Comprehensive Healthcare combines important capabilities, experience and technologies to enhance access to laboratory services. All these are expected to positively impact the company’s revenues in the fourth quarter.
Labcorp Price and EPS Surprise
Labcorp price-eps-surprise | Labcorp Quote
Labcorp is also likely to have continued to innovate and launch new tests in important therapeutic areas by harnessing science, technology and innovation. The Invitae acquisition has bolstered its specialty testing capabilities, enabling the company to use genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases.
By integrating its cutting-edge genetic testing solutions, LH is now able to offer more comprehensive patient insights, covering everything from testing and diagnosis to treatment. In the oncology area, Labcorp’s status as the only provider of FDA-authorized kitted solutions for both tissue and liquid-based solid tumor testing is likely to have secured its competitive edge, contributing to the fourth-quarter top line.
We also expect Labcorp to have gained from its growing consumer-initiated test offerings on the Labcorp OnDemand channel. In October 2024, the company announced an exclusive agreement with NowDiagnostics to distribute the first over-the-counter, point-of-care Syphilis blood test granted marketing authorization by the FDA.
The Zacks Consensus Estimate indicates a 9.4% year-over-year increase in the Dx segment’s revenues in the fourth quarter of 2024.
Biopharma Laboratory Services (BLS)
The segment is likely to have benefited from continued strength in the Central Laboratories business, its largest component. Labcorp’s Global Trial Connect suite digital and data solutions are expected to have seen strong customer adoption, supported by the latest enhancements that aimed for improved site workflow efficiency and facilitated deeper insights through continued collaboration across sponsors and sites. Additionally, the Early Development unit may have witnessed improved gross orders and cancellations, boosting the overall revenues in the fourth quarter of 2024.
According to the Zacks Consensus Estimate, revenues in the BLS segment are likely to improve 7.6% year over year.
From an operational standpoint, we expect Labcorp to have met its targeted annual savings of $100-$125 million through its Launchpad initiative. For the fourth quarter of 2024, the Zacks Consensus Estimate implies an 8.2% increase in the adjusted operating income for the Dx business, while the same for the BLS arm indicates a 12.9% improvement year over year.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. This is exactly the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of +0.12%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
Masimo MASI has an Earnings ESP of +4.05% and a Zacks Rank #1. The company is set to release fourth-quarter 2024 results on Feb. 25.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 14.4% from the year-ago quarter figure.
Merit Medical Systems MMSI has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS is expected to increase 2.47% from the year-ago quarter figure.
Cencora COR has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is set to release first-quarter fiscal 2025 results on Feb. 2.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.45%. The Zacks Consensus Estimate for COR’s first-quarter EPS is expected to increase 7% from the year-ago reported figure.
Zacks Investment Research
The fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports indicate several key growth drivers at play, including increased patient volumes, utilization, admissions, patient days and rate hikes, as well as growing demand for commercial healthcare plans and technology-enabled offerings. However, rising medical costs due to increased utilization and occupancy have partly offset the positives.
Based on our exclusive research and unique market insight, we present four stocks — Amgen Inc. AMGN, Cencora, Inc. COR, Humana Inc. HUM and Ardent Health Partners, Inc. ARDT — which are set to beat earnings estimates this earnings season.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Q4 Expectations
Before delving into the specifics of what could have impacted fourth-quarter performance, let's examine the sector forecasts.
The healthcare space is a part of the broader Zacks Medical sector (one of the 16 broad Zacks sectors within the Zacks Industry). According to the latest Earnings Trends report dated Jan. 29, the medical sector is projected to experience 12.5% growth in earnings for the fourth quarter, while revenues are anticipated to rise by 8.6%.
Factors at Play for Healthcare Stocks in Q4
The healthcare sector is vast and complex, covering hospitals, medical services, nursing homes, health insurance, medical devices, pharmaceuticals, and outpatient and home healthcare. A growing aging population and rising demand for healthcare products and services continue to drive sales for industry players.
However, investments in technology and innovation have likely pressured profit margins in the short term. Higher salaries and benefits have also increased overall costs for healthcare companies. Additionally, some HMO companies are expected to have seen a decline in Medicaid and Medicare memberships due to redeterminations.
The patient volumes likely rose in the fourth quarter, driven by more visits and surgeries. Increased revenue per admission should have further boosted top-line growth. The continued resumption of elective procedures, particularly among seniors, also contributed to higher patient volumes. However, this surge in utilization may have led to higher medical costs, potentially squeezing profit margins.
To offset rising medical cost trends, some companies likely implemented premium rate hikes, providing some financial relief. Health insurers may have also benefited from new product offerings, technological advancements, premium growth and increased investment income. Meanwhile, the demand for affordable healthcare plans may have driven higher membership in the commercial market.
On the positive side, technological innovations continue to reshape the healthcare industry. AI and automation are improving clinical workflows, enhancing diagnostics and reducing unnecessary costs. These advancements have likely helped hospitals optimize services, shorten patient wait times, enhance the overall patient experienceand lower treatment expenses.
How to Identify Potential Outperformers?
Identifying healthcare stocks with the potential for an earnings beat can be challenging amid the crowded investment landscape. However, our proprietary methodology simplifies this task, offering insights into potential outperformers. With our unique research and deep market analysis, we've identified the healthcare stocks using the Zacks Stock Screener.
These stocks have the ideal combination of two ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to surpass expectations. Our research shows that for stocks with this combination, the chances of an earnings beat are as high as 70%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Potential Outperformers
One might start with Cencora, which is one of the major pharmaceutical services companies. Headquartered in Conshohocken, PA, the company’s December-quarter earnings are expected to have benefited from increased sales of GLP-1 drugs and specialty products and higher operating income from the global specialty logistics business. Higher days payable and growth in the U.S. Healthcare Solutions business are likely to have positioned the company for an earnings beat this time around.
The Zacks Consensus Estimate for Cencora’s fiscal first-quarter earnings is pegged at $3.50 per share, which remained stable over the past week. It beat earnings estimates in all the past four quarters, with an average of 7%. COR has an Earnings ESP of +0.63% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cencora, Inc. Price and EPS Surprise
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
You may also watch Thousand Oaks, CA-based Amgen, one of the biggest biotech companies in the world, which has an Earnings ESP of +3.15% and a Zacks Rank #3.
Its fourth-quarter earnings are likely to have gained from growing product sales in Prolia, Repatha, Kyprolis, Xgeva, Vectibix and others. Growth in rare disease drugs, mostly Horizon’s products, will likely boost its results. The Zacks Consensus Estimate for Amgen’s fourth-quarter earnings indicates a 6.4% improvement from a year ago. The estimate remained stable over the past week. It beat earnings estimates in each of the past four quarters, the average surprise being 4.1%.
Amgen Inc. Price and EPS Surprise
Amgen Inc. price-eps-surprise | Amgen Inc. Quote
Louisville, KY-based Humana also deserves mention. It is a healthcare plan provider witnessing strong premium growth, improving cost management and growing memberships. It has an Earnings ESP of +0.23% and a Zacks Rank #3. The consensus mark for fourth-quarter revenues is pegged at $28.82 billion.
An expanding value-based home care model is expected to benefit HUM’s CenterWell unit. The Zacks Consensus Estimate for Humana’s fourth-quarter earnings remained stable over the past week with no revisions in estimates. It beat earnings estimates thrice in the past four quarters and missed once, the average surprise being 0.2%.
Humana Inc. Price and EPS Surprise
Humana Inc. price-eps-surprise | Humana Inc. Quote
Finally, we have Brentwood, TN-based Ardent Health, which provides healthcare services through a network of hospitals and clinics. Rising adjusted admissions, higher revenue per admission and patient days are likely to have positioned ARDT for better-than-expected fourth-quarter earnings.
The Zacks Consensus Estimate for Ardent Health’s bottom line for the to-be-reported is pegged at 45 cents per share, which remained stable over the past week. The consensus mark for revenues is pegged at $1.49 billion. ARDT has an Earnings ESP of +0.74% and a Zacks Rank #3. It beat earnings estimates once and missed one time in the past two quarters.
Ardent Health Partners, Inc. Price and EPS Surprise
Ardent Health Partners, Inc. price-eps-surprise | Ardent Health Partners, Inc. Quote
Zacks Investment Research
Edwards Lifesciences Corporation EW is expected to report fourth-quarter 2024 results shortly.
See the Zacks Earnings Calendar to stay ahead of market-making news.
In the last reported quarter, the company’s adjusted earnings per share of 67 cents were in line with the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing four quarters and matched estimates in the other three. EW has a trailing four-quarter earnings surprise of 0.78% on average.
Q4 Estimates
The Zacks Consensus Estimate for the company’s fourth-quarter 2024 revenues is pegged at $1.36 billion, suggesting an 11.2% decline from the year-ago reported figure.
The Zacks Consensus Estimate for fourth-quarter 2024 net earnings of 55 cents per share indicates a 14.1% drop from the year-ago reported figure.
For the fourth quarter of 2024, the company projected total sales to be between $1.33 billion and $1.39 billion. It expects adjusted EPS in the band of 53 cents to 57 cents.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
The Zacks Consensus Estimate for earnings has been unchanged over the past 30 days.
Factors at Play
Similar to the last reported quarter, Edwards Lifesciences is likely to have gained from its patient-focused innovation strategy. A favorable hospitalization trend, strong global adoption of transcatheter heart valves and improved procedural volume are expected to have driven growth in the fourth quarter. However, the absence of Critical Care business operation through September is likely to have impacted the full fourth-quarter total revenues of Edwards Life Sciences.
On Sept. 3, 2024, the company announced the completion of the sell-off of the Critical Care product group to Becton, Dickinson and Company or BD, for a total value of $4.2 billion. This business recorded full-quarter revenues of $246 million in the second quarter of 2024, reflecting 7% year-over-year growth. The absence of this segment for an entire quarter is expected to have a significant impact on the company's fourth-quarter revenues on a year-over-year basis.
Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong demand for the company’s SAPIEN platform is expected to have acted as the primary growth factor. SAPIEN currently constitutes the majority of the company’s sales within the United States.
However, at the time of the third-quarter earnings release, the company talked about certain regional pressures hampering growth within the segment. In the third quarter, in Japan, slower market growth put pressure on results. This might have continued even in the fourth quarter.
For the fourth quarter, EW’s earlier-provided guidance assumed year-over-year TAVR growth below the full-year TAVR growth expectation of 5% to 7%. One of the reasons behind this was a tough year-over-year comparison. Further, the impact from hurricanes in the southeast, as well as a one-time impact from a China distributor rebate adjustment during the to-be-reported quarter are expected to have impacted the performance within TAVR.
The company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) segment’s PASCAL platform is likely to have maintained strong growth momentum in the fourth quarter globally, backed by its portfolio of differentiated therapies, positive pivotal trial results to support approvals and adoption and favorable real-world clinical outcomes. The TMTT segment’s performance is expected to have been driven by the strong adoption of the differentiated PASCAL Precision platform across the United States and Europe. Further, the company is expected to have gained business with the continued adoption of the EVOQUE tricuspid replacement system and the strong performance of the SAPIEN M3 mitral replacement system in the United States and Europe.
Our model estimates the Transcatheter Heart Valves business to report revenues of $1.10 billion, implying a 5.9% improvement from the year-ago period.
Within Surgical Structural Heart, the company is expected to have recorded strong fourth-quarter growth, banking on the penetration of its premium products across all regions.
Edwards Lifesciences is likely to have gained from strong global adoption of its premium RESILIA technology and improvement in procedural volumes. Edwards Lifesciences is expected to have seen strong global adoption of premium surgical technologies, including the MITRIS RESILIA valve, INSPIRIS and KONECT. In the fourth quarter, the company is expected to have witnessed procedure growth globally within Surgical.
Our model estimates the segment’s fourth-quarter revenues to be $264.8 million, suggesting a 6.7% rise from the year-ago quarter’s reported figure.
However, staffing shortages, which reduced hospital capacity, and choppy market conditions due to a difficult geopolitical situation are likely to have impeded the company’s growth in the quarter to be reported.
What Our Quantitative Model Predicts
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of beating estimates. This is not the case here, as you can see:
Earnings ESP: Edwards Lifesciences has an Earnings ESP of -0.03%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to post an earnings beat this quarter.
Masimo MASI has an Earnings ESP of +4.05% and a Zacks Rank #1. The company is set to release fourth-quarter 2024 results on Feb. 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies an increase of 14.4% from the year-ago quarter reported figure.
Merit Medical Systems MMSI has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter earnings implies an increase of 2.5% from the year-ago quarter figure.
Cencora COR has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is set to release first-quarter fiscal 2025 results on Feb. 2.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.45%. The Zacks Consensus Estimate for COR’s first-quarter EPS suggests an increase of 7% from the year-ago reported figure.
Zacks Investment Research
Bio-Techne Corporation TECH is set to release its second-quarter fiscal 2025 results on Feb. 5, before the opening bell.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 42 cents in the last reported quarter, which exceeded the Zacks Consensus Estimate by 10.53%. The company topped earnings estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.55%.
Q2 Estimates for TECH
For the fiscal second quarter, the Zacks Consensus Estimate for Bio-Techne’s revenues is pegged at $285.3 million, indicating an increase of 4.7% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s second-quarter fiscal 2025 EPS suggests a 5% decline to 38 cents.
Estimates for Bio-Techne’s fiscal second-quarter earnings have remained unchanged in the past 90 days.
Bio-Techne Corp Price and EPS Surprise
Bio-Techne Corp price-eps-surprise | Bio-Techne Corp Quote
Factors Influencing Bio-Techne's Fiscal Q2 Performance
Bio-Techne’s cell and gene therapy vertical within the Protein Sciences segment has shown continued traction in recent quarters, banking on strong performances of the company’s proteomic reagent and scalable workflow solutions that enable customers to accelerate e-clinical, clinical and eventually aid in the commercialization of these next-generation therapeutics. New customer additions over the past two years have led to a significant expansion of this business. In the fiscal second quarter, the company is expected to have witnessed improved stabilization from large- pharma customers and an increase in ordering trends from biotech customers.
Further, the company’s newly added Simple Western platform called Leo (a high-throughput automated western blot system, enabling the simultaneous analysis of up to 100 samples in a single three-hour run) gained significant customer interest in the first quarter of fiscal 2025, being increasingly used for absolute protein quantitation and relative potency assay. This might have contributed to the top line in the fiscal second quarter.
A gradually easing biotech funding scenario might have increased biotech spending, contributing to the company’s business.
The consensus estimate for Protein Sciences revenues is pegged at $197.7 million for the fiscal second quarter, almost in line with the year-ago period reported figure.
Within the Diagnostics and Spatial Biology segment (previously referred to as the Diagnostics and Genomics segment), in the Spatial Biology growth vertical, despite the budget reset by pharma customers, Bio-Techne is expected to have witnessed solid growth, banking on the strong adoption of the company’s new spatial biology instrument COMET.
In the calendar year 2024, Bio-Techne enabled RNA detection and visualization on COMET with the launch of RNAscope HiPlex capabilities for the instrument. Following this launch, COMET is now capable of detecting and visualizing up to 24 plate proteins and 12 RNA targets simultaneously, creating a highly differentiated multiomic system for the rapidly growing spatial biology market. These enhanced capabilities are expected to have expanded the company’s business in the fiscal second quarter.
The launch of Bio-Techne's R&D system branded antibodies validated for use on the COMET is also expected to have aided the company.
Meanwhile, the Molecular Diagnostics growth vertical is already in growth acceleration mode as its unique and underpenetrated portfolio of products (including ExoDx prostate test and Asuragen kit business) continues to take market share. In the fiscal second quarter, too, this trend is likely to have continued, banking on the ongoing traction and market adoption of this portfolio.
The consensus estimate for Diagnostics and Spatial Biology revenues is pegged at $75.4 million for the fiscal second quarter, which implies no change from the year-ago period reported figure.
What Our Model Unveils for TECH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
MedTech Stocks to Consider
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Masimo MASI has an Earnings ESP of +4.05% and a Zacks Rank #1. The company is set to release fourth-quarter 2024 results on Feb. 25. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.10%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS indicates an increase of 14.4% from the year-ago quarter reported figure.
Merit Medical Systems MMSI has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is slated to release fourth-quarter 2024 results on Feb. 25.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.42%. The Zacks Consensus Estimate for Merit Medical’s fourth-quarter EPS suggests an increase of 2.5% from the year-ago quarter reported figure.
Cencora COR has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is set to release first-quarter fiscal 2025 results on Feb. 2.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 2.45%. The Zacks Consensus Estimate for COR’s first-quarter EPS implies an increase of 7% from the year-ago reported figure.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.